209 related articles for article (PubMed ID: 11948965)
1. Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer.
Segawa Y; Yoshimura R; Hase T; Nakatani T; Wada S; Kawahito Y; Kishimoto T; Sano H
Prostate; 2002 May; 51(2):108-16. PubMed ID: 11948965
[TBL] [Abstract][Full Text] [Related]
2. Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors.
Matsuyama M; Yoshimura R; Mitsuhashi M; Hase T; Tsuchida K; Takemoto Y; Kawahito Y; Sano H; Nakatani T
Int J Oncol; 2004 Apr; 24(4):821-7. PubMed ID: 15010818
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of cysteinyl LT1 receptor in prostate cancer and CysLT1R antagonist inhibits prostate cancer cell growth through apoptosis.
Matsuyama M; Hayama T; Funao K; Kawahito Y; Sano H; Takemoto Y; Nakatani T; Yoshimura R
Oncol Rep; 2007 Jul; 18(1):99-104. PubMed ID: 17549353
[TBL] [Abstract][Full Text] [Related]
4. INSL3 in the benign hyperplastic and neoplastic human prostate gland.
Klonisch T; Müller-Huesmann H; Riedel M; Kehlen A; Bialek J; Radestock Y; Holzhausen HJ; Steger K; Ludwig M; Weidner W; Hoang-Vu C; Hombach-Klonisch S
Int J Oncol; 2005 Aug; 27(2):307-15. PubMed ID: 16010410
[TBL] [Abstract][Full Text] [Related]
5. Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists.
Sato H; Ishihara S; Kawashima K; Moriyama N; Suetsugu H; Kazumori H; Okuyama T; Rumi MA; Fukuda R; Nagasue N; Kinoshita Y
Br J Cancer; 2000 Nov; 83(10):1394-400. PubMed ID: 11044367
[TBL] [Abstract][Full Text] [Related]
6. Expression of cyclooxygenase-2 in prostate carcinoma.
Yoshimura R; Sano H; Masuda C; Kawamura M; Tsubouchi Y; Chargui J; Yoshimura N; Hla T; Wada S
Cancer; 2000 Aug; 89(3):589-96. PubMed ID: 10931458
[TBL] [Abstract][Full Text] [Related]
7. Expression of peroxisome proliferator-activated receptor (PPAR)-gamma in human lung cancer.
Inoue K; Kawahito Y; Tsubouchi Y; Yamada R; Kohno M; Hosokawa Y; Katoh D; Bishop-Bailey D; Hla T; Sano H
Anticancer Res; 2001; 21(4A):2471-6. PubMed ID: 11724309
[TBL] [Abstract][Full Text] [Related]
8. Amphiregulin expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 93 cases.
Bostwick DG; Qian J; Maihle NJ
Prostate; 2004 Feb; 58(2):164-8. PubMed ID: 14716741
[TBL] [Abstract][Full Text] [Related]
9. Human telomerase reverse transcriptase expression correlates with vascular endothelial growth factor-promoted tumor cell proliferation in prostate cancer.
Tang J; Wang Z; Li X; Li J; Shi H
Artif Cells Blood Substit Immobil Biotechnol; 2008; 36(2):83-93. PubMed ID: 18437586
[TBL] [Abstract][Full Text] [Related]
10. Interferon-gamma and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression.
Royuela M; de Miguel MP; Ruiz A; Fraile B; Arenas MI; Romo E; Paniagua R
Eur Cytokine Netw; 2000 Mar; 11(1):119-27. PubMed ID: 10705309
[TBL] [Abstract][Full Text] [Related]
11. Expression of peroxisome proliferator-activated receptor gamma and the growth inhibitory effect of its synthetic ligands in human salivary gland cancer cell lines.
Begum NM; Nakashiro K; Kawamata H; Uchida D; Shintani S; Ikawa Y; Sato M; Hamakawa H
Int J Oncol; 2002 Mar; 20(3):599-605. PubMed ID: 11836575
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor alpha is an androgen-responsive gene in human prostate and is highly expressed in prostatic adenocarcinoma.
Collett GP; Betts AM; Johnson MI; Pulimood AB; Cook S; Neal DE; Robson CN
Clin Cancer Res; 2000 Aug; 6(8):3241-8. PubMed ID: 10955810
[TBL] [Abstract][Full Text] [Related]
13. The effect of peroxisome proliferator-activated receptor-gamma ligand on urological cancer cells.
Yoshimura R; Matsuyama M; Hase T; Tsuchida K; Kuratsukuri K; Kawahito Y; Sano H; Segawa Y; Nakatani T
Int J Mol Med; 2003 Dec; 12(6):861-5. PubMed ID: 14612958
[TBL] [Abstract][Full Text] [Related]
14. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer.
Das S; Roth CP; Wasson LM; Vishwanatha JK
Prostate; 2007 Oct; 67(14):1550-64. PubMed ID: 17705178
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer.
Nagata D; Yoshihiro H; Nakanishi M; Naruyama H; Okada S; Ando R; Tozawa K; Kohri K
Cancer Detect Prev; 2008; 32(3):259-66. PubMed ID: 18789607
[TBL] [Abstract][Full Text] [Related]
16. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development.
Ishiguro H; Nakaigawa N; Miyoshi Y; Fujinami K; Kubota Y; Uemura H
Prostate; 2005 Jun; 64(1):92-100. PubMed ID: 15666359
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of cathepsin X in prostate cancer and prostatic intraepithelial neoplasia.
Nägler DK; Krüger S; Kellner A; Ziomek E; Menard R; Buhtz P; Krams M; Roessner A; Kellner U
Prostate; 2004 Jul; 60(2):109-19. PubMed ID: 15162377
[TBL] [Abstract][Full Text] [Related]
18. Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists.
Yoshimura R; Matsuyama M; Segawa Y; Hase T; Mitsuhashi M; Tsuchida K; Wada S; Kawahito Y; Sano H; Nakatani T
Int J Cancer; 2003 May; 104(5):597-602. PubMed ID: 12594814
[TBL] [Abstract][Full Text] [Related]
19. Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells.
Subbarayan V; Sabichi AL; Kim J; Llansa N; Logothetis CJ; Lippman SM; Menter DG
Cancer Epidemiol Biomarkers Prev; 2004 Nov; 13(11 Pt 1):1710-6. PubMed ID: 15533897
[TBL] [Abstract][Full Text] [Related]
20. Expression and function of peroxisome proliferator-activated receptors in human melanocytes.
Kang HY; Chung E; Lee M; Cho Y; Kang WH
Br J Dermatol; 2004 Mar; 150(3):462-8. PubMed ID: 15030328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
